Four-Drug cocktail aims to make inoperable liver cancer removable
NCT ID NCT07012798
First seen May 14, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tests a new approach for people with advanced liver cancer that cannot be removed with surgery. Participants receive a sequence of treatments: chemotherapy directly into the liver, two drugs (durvalumab and bevacizumab) that boost the immune system and block blood vessel growth, and finally targeted radiation. The goal is to shrink the tumor enough to allow surgical removal. About 30 adults with intermediate or advanced liver cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300308, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.